34 Predictive value of PD-L1 expression IHC on histology vs. cytology-specimen in non-small cell lung cancer (NSCLC) cohort in Leicester
Checkpoint inhibitors (CPI), especially anti PD-1/anti PD-L1 antibodies, have transformed the treatment paradigm of NSCLC, especially in those without actionable targetable driver mutations. PD-1 is expressed on tumour-infiltrating immune cells and PD-L1 is expressed on antigen presenting cell and tumour cells. PD-L1 expression is detected using immunohistochemistry; multiple assays have been approved as companion diagnostics to a particular CPI. The Blueprint phase II clinical trial highlighted the differing level of sensitivity and reproducibility of each assay, which have important implications for patients ’ eligibility to receive CPI.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Shradha Bhagani, Anum Sultan, Anupama Vijay, Cathy Richards, Samreen Ahmed Tags: Diagnosis and Staging Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Cytology | Lung Cancer | Non-Small Cell Lung Cancer